Considerations for incorporating adjuvant nivolumab into treatment plans for appropriate patients with advanced urothelial carcinoma based on early, recently presented data.
Targeted Oncology
Articles by Targeted Oncology
Experts in hematology-oncology share factors to consider when approaching the treatment of myelofibrosis.
Experts discuss tafasitamab, a CD19-targeted monoclonal antibody (mAb) for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Loretta Nastoupil, MD, and John Burke, MD, review data from the L-MIND study presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
An overview of CD19 as a treatment target for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Insight into the combination of tafasitamab plus lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Implications for using checkpoint inhibitors as neoadjuvant treatment for patients with advanced urothelial carcinoma based on clinical trial data.
Preferences for treating patients with locally advanced urothelial carcinoma based on various factors, including disease presentation and patient preference.
Loretta Nastoupil, MD, and John Burke, MD, discuss transplant as a treatment option for patients with relapsed/refractory [R/R] diffuse large B-cell lymphoma [DLBCL], as well as treatment options for patients with relapsed disease after transplant.
Loretta Nastoupil, MD, and John Burke, MD, provide insight into treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Loretta Nastoupil, MD, and John Burke, MD, provide an overview of different prognostic factors that have been identified in diffuse large B-cell lymphoma (DLBCL).
John Mascarenhas, MD, and Ruben Mesa, MD, provide insight on the diagnosis and prognosis of myelofibrosis.
Loretta Nastoupil, MD, and John Burke, MD, discuss the therapeutic landscape for patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and begin with an overview of the disease.
The doctors discuss new discoveries that may lead to a cure for MPNs.
The experts describe a new drug under review by the FDA that offers an option for patients with MPNs and low platelets and discuss what they are looking forward to in the next 3-5 years.
The doctors discuss withdrawing patients with MPNs from a JAK inhibitor, titration, and rechallenging.
Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.
Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.
The relationship between germline mutations in DNA repair genes and advanced urothelial carcinoma, and tips for counseling patients who are candidates for germline testing.
Disease characteristics and risk factors associated with urothelial carcinoma that create a significant burden for patients, loved ones, and health care professionals across the globe.
Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.
Additional treatment options for low- and high-risk patients with MPNs are discussed.
Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.
A discussion of JAK inhibitors, risk models, quality of life, splenomegaly, and other issues in treating patients with MF.
The progression of disease in MPNs and how genetic testing may inform therapy.
A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.
Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.
Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.
The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.
Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.